利妥昔单抗治疗淋巴瘤患者致乙型肝炎病毒再激活一例
被引量:1
摘要
患者男,70岁。因乏力,皮肤、巩膜黄染10 d ,于2013年9月收住入院。否认乙型肝炎病史,未接种过乙型肝炎疫苗。2011年1月经活组织病理检查诊断为,大细胞(弥漫性)非霍奇金淋巴瘤,弥漫性大 B 细胞淋巴瘤。肝功能正常,抗‐HBs阳性,余均为阴性,未检测 HBV DNA 。
出处
《中华传染病杂志》
CAS
CSCD
北大核心
2016年第6期369-370,共2页
Chinese Journal of Infectious Diseases
基金
国家自然科学基金(81402559)
参考文献10
-
1Plosker GL, Figgitt DP. Rituximab: a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukaemia[J]. Drugs, 2003, 63 (8): 803-843. DOI: 10. 2165/00003495- 200363080-00005.
-
2Civan J, Hann HW. Giving rituximab in patients with occult orresolved hepatitis B virus infection: are the current guidelines good enough?[J]. Expert Opin Drug Saf, 2015,14(6):865- 875. DOI: 10. 1517/14740338. 2015. 1032243.
-
3陶晨,叶伟,艾敏,杜建霞.利妥昔单抗致乙型肝炎病毒再激活一例[J].中华临床医师杂志(电子版),2013,7(5):47-47. 被引量:3
-
4Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study [J]. Hepatology, 2014,59 (6) : 2092-2100. DOI: 10. 1002/hep. 26718.
-
5Ceccarelli L, Salpini R, Sarmati L,et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy [J]. J Infect, 2012,65 (2) : 180- 183. DOI: 10.1016/j. jinf. 2011.11. 021.
-
6Srivastava A, Mathias A, Yachha SK,et al. Occult hepatitis B infection in children with chronic liver disease[J]. Eur J Gastroenterol Hepatol, 2015,27 (4):375-377. DOI; 10. 1097/MEG. 0000000000000294.
-
7周姗,杜鹏,郑欣,叶贤林,曾劲峰,卢亮,朱为刚,杨宝成,李婷婷,黎诚耀.2010年至2012年深圳地区献血者隐匿性乙型肝炎病毒感染的分子病毒学特征[J].中华传染病杂志,2015,33(3):150-153. 被引量:9
-
8何水珍,苏成豪,沈理通,牛建军.厦门市自然人群中乙型肝炎病毒隐匿性感染状况调查[J].中华预防医学杂志,2015,49(2):132-136. 被引量:15
-
9中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华传染病杂志,2011,29(1):65-80.
-
10European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection [J].J Hepatol, 2012,57(1) :167-185. DOI:10. 1016/j. jhep. 2012.02. 010.
二级参考文献18
-
1zcan eneli,Zübeyde Nur zkurt,Kadir Acar,Seyyal Rota,Sahika Zeynep Aki,Zeynep Arzu Yegin,Münci Yagci,Seren zenirler,Gülsan Türkz Sucak.Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients[J].World Journal of Gastroenterology,2010,16(14):1765-1771. 被引量:3
-
2Garcia-Montalvo BM, Farfdn-Ale JA, Acosta-Viana KY, et al. Hepatitis B virus DNA in blood donors with anti-HBc as a possible indicator of active hepatitis B virus infection in Yucatan, Mexico rJ~. Transfus Med, 2005,15(5):371-378.
-
3Allain JP. Occult hepatitis B virus infection [J~. Transfus Clin Biol, 2004,11(1) :18-25.
-
4Allain JP, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors [-J~. Hepatology, 2009,49(6) : 1868-1876.
-
5Candotti D, Grabarczyk P, Ghiazza P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains [-J']. J Hepatol, 2008,49(4) ..537-547.
-
6Zheng X, Ye X, Zhang L, et al. Characterization of occult hepatitis B virus infection from blood donors in China [-J~. J Clin Microbiol, 2011,49(5) ~ 1730-1737.
-
7Candotti D, Danso K, Allain JP. Maternofetal transmission of hepatitis B virus genotype E in Ghana, west Africa FJ~. J Gen Virol, 2007,88(Pt 10) ..2686-2695.
-
8Yuen MF, Wong DK, Lee CK, et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection l-J~. Clin Infect Dis, 2011,52(5) :624-632.
-
9Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study I-J]. Gastroenterology, 2003,125(2) :444-451.
-
10Wang ]T, Wang TH, Shoo ]C, et al. Detection of hepatitis B virus DNA by polymerase ehain reaetion in plasma of volunteer blood donors negative for hepatitis B surfaee antigen EJ]. J Infect Dis, 1991,163(2) ~397-399.
共引文献33
-
1陈悦,毛乾国.血清HBsAg的研究概述[J].医学信息(医学与计算机应用),2016,29(36):28-29.
-
2李国军,喻一奇,范平,邵凌云,陈少隆,洪捷敏,修自力,林琪,李昌水,张文宏.乙型肝炎表面抗原水平对核苷(酸)类似物序贯联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者的疗效预测[J].中华传染病杂志,2014,32(2):100-106. 被引量:28
-
3谭英.HBsAg阳性者胃癌术后化疗后再激活的临床分析[J].江西医药,2014,49(1):53-55. 被引量:1
-
4陶晨,叶伟,艾敏,杜建霞.利妥昔单抗致乙型肝炎病毒再激活一例[J].中华临床医师杂志(电子版),2013,7(5):47-47. 被引量:3
-
5钱雪梅,胡洁华.阿德福韦酯联合苦参素治疗HBeAg阳性慢性乙型肝炎临床观察[J].现代中西医结合杂志,2014,23(21):2368-2370. 被引量:5
-
6李良燕.病毒性肝炎患者干扰素治疗时焦虑抑郁心理的护理干预[J].实用临床医药杂志,2014,18(12):121-123. 被引量:12
-
7徐建军,潘锋,徐虹.中药正肝汤对乙型肝炎肝硬化患者血清瘦素、脂联素水平以及胰岛素抵抗影响的分析[J].中华流行病学杂志,2015,36(4):399-401. 被引量:14
-
8刘洪波,单洪.抗病毒治疗对慢性乙型肝炎患者补体的影响[J].中国实用乡村医生杂志,2015,0(8):23-24. 被引量:1
-
9袁松松,向天新,陶学萍,郭声,刘娟,李小鹏,张长林,邬小萍.乙型肝炎e抗原对人外周血单个核细胞Toll样受体9及CD8细胞活化相关分子的研究[J].中华传染病杂志,2015,33(4):220-224. 被引量:1
-
10杨澍,史海雯,高秀清,洪阁,高杉.单克隆抗体药物致不良反应132例文献分析[J].中国药房,2015,26(23):3223-3225. 被引量:2
同被引文献5
-
1Timothée Noterdaeme,Luc Longrée,Christian Bataille,Arnaud Deroover,Anne Lamproye,Jean Delwaide,Yves Beguin,Pierre Honoré,Olivier Detry.Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients[J].World Journal of Gastroenterology,2011,17(25):3069-3072. 被引量:6
-
2宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉.314例药物性肝衰竭患者临床特征分析[J].实用肝脏病杂志,2019,22(2):216-219. 被引量:5
-
3中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组,李兰娟,韩涛.肝衰竭诊治指南(2018年版)[J].中华传染病杂志,2019,37(1):1-9. 被引量:499
-
4吴欣,郭杨志,杜霄壤,吴孟晋,朱云,冯兴中.75例中药诱导的肝损伤患者临床特征分析[J].实用肝脏病杂志,2019,22(5):668-671. 被引量:13
-
5中华医学会肝病学分会,中华医学会感染病学分会,尤红,王福生,李太生,孙亚朦,徐小元,贾继东,南月敏,王贵强,侯金林,魏来,段钟平,庄辉.慢性乙型肝炎防治指南(2022年版)[J].实用肝脏病杂志,2023,26(3). 被引量:141
-
1过小叶,朱银芳,华忠.糖皮质激素致乙型肝炎病毒再激活1例[J].现代中西医结合杂志,2011,20(15):1895-1895.
-
2魏茂周,郑嵘,董安山,王华丽.胸腺肽α1预防乙型肝炎病毒再激活临床研究[J].中国当代医药,2012,19(7):70-71. 被引量:1
-
3江守伟,周仲松,程君,徐楠,孙秋林.糖皮质激素致乙型肝炎病毒再激活临床体会附3例分析[J].肝脏,2011,16(4):352-354.
-
4梁宏.免疫抑制治疗期间乙型肝炎病毒再激活的诊断及治疗[J].中国基层医药,2010,17(20):2791-2792. 被引量:5
-
5苏菲菲,杨守峰,赵晓云,宁洪叶,蒋贤高,朱海燕,崔小亚.拉米夫定预防结核性胸膜炎合并乙型肝炎患者激素治疗后的乙型肝炎病毒再激活[J].中华传染病杂志,2012,30(10):618-619. 被引量:2
-
6彭经宙,林泉.恩替卡韦预防肺结核患者化疗后乙型肝炎病毒再激活的疗效研究[J].现代诊断与治疗,2014,25(24):5591-5592. 被引量:2
-
7刘永振,王杰,陈香梅,鲁凤民.乙型肝炎病毒再激活研究进展[J].肝脏,2014,19(10):777-781. 被引量:6
-
8谢能文,何金秋.免疫抑制剂致乙型肝炎病毒再激活11例分析[J].实用临床医学(江西),2013,14(6):35-37.
-
9廖献花,马博,林菁华,徐雅,刘思纯.糖皮质激素致乙型肝炎病毒再激活死亡1例并文献复习[J].肝脏,2010,15(1):65-67.
-
10李薇薇.血液病患者治疗后乙型肝炎病毒再激活的临床治疗[J].人人健康,2016,0(4):56-56.